RT Journal Article
SR Electronic
T1 Prevalence of anti-SARS-CoV-2 immunity in Kazakhstan before the launch of COVID-19 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.03.21262885
DO 10.1101/2021.09.03.21262885
A1 Kadyrova, Irina
A1 Yegorov, Sergey
A1 Negmetzhanov, Baurzhan
A1 Kolesnikova, Yevgeniya
A1 Kolesnichenko, Svetlana
A1 Korshukov, Ilya
A1 Vazenmiller, Dmitriy
A1 Stupina, Yelena
A1 Kabildina, Naylya
A1 Ashimova, Assem
A1 Raimbekova, Aigul
A1 Turmukhambetova, Anar
A1 Miller, Matthew S.
A1 Hortelano, Gonzalo
A1 Babenko, Dmitriy
YR 2021
UL http://medrxiv.org/content/early/2021/12/08/2021.09.03.21262885.abstract
AB Background COVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, we assessed the prevalence of anti-SARS-CoV-2 antibody-mediated immunity in a heterogeneous cohort of public university employees in Karaganda, Kazakhstan.Methods Asymptomatic subjects (n=100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)-reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds.Results Anti-S IgG and IgA seropositivity rates among SARS-CoV-2 PCR-negative participants (n=100) were 42% (95% CI [32.2-52.3]) and 59% (95% CI [48.8-69.0]), respectively, and 64% (95% CI [53.4-73.1]) of the cohort tested positive for at least one of the antibodies. Anti-S IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity and self-reported history of respiratory illness since March 2020.Conclusions SARS-CoV-2 exposure in this cohort is ∼15-fold higher compared to the reported all-time national and regional COVID-19 prevalence. Continuous serological surveillance is critical for understanding the COVID-19 transmission dynamics and should be nationally implemented to better inform the public health response in Central Asia.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04871841Funding StatementThe study was funded by the Ministry of Education and Science of the Republic of Kazakhstan (AP09259123). SY was supported, in part, by a M.G. DeGroote Postdoctoral Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The investigation was approved by Bioethic council of Karaganda Medical University (#45)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWE declare that data referred to the manuscript are availabile.